Last reviewed · How we verify

Nivolumab/rHuPH20 — Competitive Intelligence Brief

Nivolumab/rHuPH20 (Nivolumab/rHuPH20) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor with subcutaneous delivery enhancer. Area: Oncology.

phase 3 PD-1 inhibitor with subcutaneous delivery enhancer PD-1 (programmed death receptor-1) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Nivolumab/rHuPH20 (Nivolumab/rHuPH20) — Bristol-Myers Squibb. Nivolumab is a PD-1 inhibitor that blocks immune checkpoint signaling, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous drug delivery and bioavailability.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nivolumab/rHuPH20 TARGET Nivolumab/rHuPH20 Bristol-Myers Squibb phase 3 PD-1 inhibitor with subcutaneous delivery enhancer PD-1 (programmed death receptor-1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor with subcutaneous delivery enhancer class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nivolumab/rHuPH20 — Competitive Intelligence Brief. https://druglandscape.com/ci/nivolumab-rhuph20. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: